» Articles » PMID: 38436832

SOX9 Promotes Collagen VI Secretion by Upregulating PCOLCE in Neurofibroma

Overview
Journal Mol Neurobiol
Date 2024 Mar 4
PMID 38436832
Authors
Affiliations
Soon will be listed here.
Abstract

Neurofibromatosis type 1 (NF1) is caused by NF1 gene mutations. Patients with NF1 often have complications with tumors, such as neurofibroma. In order to investigate the pathogenesis of human neurofibroma, a systematic comparison of protein expression levels between Schwann cell-like sNF96.2 cells, which originated from malignant peripheral nerve sheath tumors (MPNST), and normal Schwann cells was performed using 4-D label-free proteomic analysis. In addition, the expression levels and localization of dysregulated proteins were confirmed using a Gene Expression Omnibus (GEO) transcriptomic dataset, Western blot analysis, and immunofluorescence labeling. The effects of SRY-box transcription factor 9 (SOX9) in the neurofibroma and surrounding microenvironment were evaluated in vivo using a tumor transplantation model. The present study observed that SOX9 and procollagen C-endopeptidase enhancer (PCOLCE) were significantly altered. NF1 mutation promoted the nuclear translocation and transcriptional activity of SOX9 in neurofibromas. SOX9 increased collagen VI secretions by enhancing the activation of PCOLCE in neurofibroma cells. These findings might provide new perspectives on the pathophysiological significance of SOX9 in neurofibromas and elucidate a novel molecular mechanism underlying neurofibromas.

Citing Articles

Discoidin domain receptor inhibitor DDR1-IN-1 induces autophagy and necroptotic cell death in malignant peripheral nerve sheath tumor.

Lai G, Lee Y, Weng H, Lai K, Hsiang M, Hsu K Cell Death Discov. 2025; 11(1):83.

PMID: 40025071 PMC: 11873111. DOI: 10.1038/s41420-025-02367-2.


Procollagen C-protease enhancer protein promotes glioma growth by activating ERK signaling.

Ma Z, Huang D, Ru L, Chen M Asia Pac J Clin Oncol. 2024; 21(1):48-57.

PMID: 39403870 PMC: 11733849. DOI: 10.1111/ajco.14127.

References
1.
Bok S, Shin D, Yallowitz A, Eiseman M, Cung M, Xu R . MEKK2 mediates aberrant ERK activation in neurofibromatosis type I. Nat Commun. 2020; 11(1):5704. PMC: 7658220. DOI: 10.1038/s41467-020-19555-6. View

2.
Jiang C, McKay R, Le L . Tumorigenesis in neurofibromatosis type 1: role of the microenvironment. Oncogene. 2021; 40(39):5781-5787. PMC: 8713356. DOI: 10.1038/s41388-021-01979-z. View

3.
Arnold S, Payne J, Lorenzo J, North K, Barton B . Preliteracy impairments in children with neurofibromatosis type 1. Dev Med Child Neurol. 2018; 60(7):703-710. DOI: 10.1111/dmcn.13768. View

4.
Hyman S, Shores E, North K . Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol. 2006; 48(12):973-7. DOI: 10.1017/S0012162206002131. View

5.
Castle B, Baser M, Huson S, Cooper D, Upadhyaya M . Evaluation of genotype-phenotype correlations in neurofibromatosis type 1. J Med Genet. 2003; 40(10):e109. PMC: 1735293. DOI: 10.1136/jmg.40.10.e109. View